The ACME Laboratories Ltd. (DSE:ACMELAB)

Market Cap	14.77B
Revenue (ttm)	34.75B
Net Income (ttm)	2.40B
Shares Out	211.60M
EPS (ttm)	11.36
PE Ratio	6.15
Forward PE	n/a
Dividend	3.50 (5.01%)
Ex-Dividend Date	Nov 19, 2025

Volume	279,615
Average Volume	125,375
Open	71.30
Previous Close	71.50
Day's Range	69.40 - 71.50
52-Week Range	67.90 - 85.90
Beta	0.03
RSI	32.17
Earnings Date	Jan 27, 2026

About The ACME Laboratories

The ACME Laboratories Ltd., a pharmaceutical company, engages in the manufacture, market, and distribution of generic pharmaceutical formulation products in Bangladesh. The company offers pharmaceutical products in various therapeutic areas, such as allergic disorders, analgesic, antifribinolytic, anti-infective, antiviral, artificial sweeteners, cardiovascular, central nervous system (CNS), cough and cold, diabetes, eye care and preparations, gastroprokinetic, hepatobiliary, gastrointestinal, gynaecological, hand sanitizers, hormones and stero...

• Industry: Pharmaceutical Preparations
• Founded: 1954
• Employees: 9,301
• Stock Exchange: Dhaka Stock Exchange
• Ticker Symbol: ACMELAB

Financial Performance

In 2024, The ACME Laboratories's revenue was 31.93 billion, an increase of 18.49% compared to the previous year's 26.95 billion. Earnings were 2.46 billion, an increase of 6.62%.